Editor’s Note, SGLT-2 Inhibitors Special Edition, June 2015

There has been a lot of press and discussion about using SGLT-2 inhibitors in type 1 diabetes due to the risk of DKA. Many of these articles focused on what happened to patients when they got DKA and whether it could be shown if the relationship was causal or causative. When researchers dug into the studies they were able to identify a problem reason for the incidence of DKA and it actually revolved around the ability of the SGLT-2 inhibitors to lower insulin requirements too much. Check out our first featured article and find out why 0.5 units/kg of body weight is a number we should all be paying attention to.

We also have a good article on how we might add SGLT-1 inhibitors to our diabetes armada with information on a newer drug that can work on both receptors.